Text-based program to help rural cancer survivors quit smoking

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III trial evaluates the effectiveness of an eight-week text-based scheduled gradual reduction (SGR) intervention designed to assist rural cancer survivors who smoke in quitting. Participants are randomized into two groups: one receiving personalized text messages to gradually reduce smoking and the other receiving a cessation booklet. The primary goal is to assess smoking cessation rates six months after quitting, while secondary objectives include evaluating the impact on overall quality of life. Follow-up assessments will occur at 30 days and six months post-quit date.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a cancer diagnosis within the past 10 years

  \* Note: Patients with ductal carcinoma in situ (DCIS) are eligible and patients currently receiving curative treatment are eligible
* Not currently on hospice
* Currently smokes \>= 5 cigarettes daily

  \* Note: Participants who smoke cigarettes and vape are eligible. Those who only vape are ineligible
* Lives in a nonmetro/rural county (defined as having a Rural Urban Continuum Code \[RUCC\] code of 4-9) and/or a Rural-Urban Commuting area code of 4-10 and/or as defined by the Office of Management and Budget as a non-rural county large area metro census tracts of at least 400 square miles in an area with population density of 35 or less per square mile with rural-urban commuting area (RUCA) codes 2-3; and outlying metro counties without a UA. The RUCC code and RUCA (4-10) codes can be checked at: https://www.ruralhealthinfo.org/am-i-rural. Those with RUCA codes of 2-3 can be checked at https://data.hrsa.gov/tools/rural-health for eligibility
* Patient interested in participating in a smoking cessation program, and not currently participating in a smoking cessation clinical trial
* Not currently using any smoking cessation pharmacotherapy (e.g. nicotine replacement therapy, bupropion or varenicline for smoking purposes only), or currently participating in any cessation program at the time of enrollment
* Patient has a cell phone or smart phone device with texting ability
* In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish
* Age \>= 18 years
* Participant must be willing to provide a urine sample.
* Patients with impaired decision-making capacity are not eligible for this study consent

Where it's running

• Kingman Regional Medical Center
  Kingman, Arizona, United States Recruiting
• Mercy Hospital Fort Smith
  Fort Smith, Arkansas, United States Recruiting
• Saint Helena Hospital
  St. Helena, California, United States Recruiting
• Malcom Randall Veterans Administration Medical Center
  Gainesville, Florida, United States Recruiting
• Northeast Georgia Medical Center Braselton
  Braselton, Georgia, United States Recruiting
• Northeast Georgia Medical Center-Gainesville
  Gainesville, Georgia, United States Recruiting

+174 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Devon Noonan, PhD, MPH, FNP-BC
• Email: devon.noonan@duke.edu
• Phone: 919-613-9130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nicotine's Effects on Eye Movements in E-Cigarette Users

  This study tests how nicotine from e-cigarettes affects eye movements and related behaviors in adults who regularly use nicotine-containing e-cigarettes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07604246

• Tobacco and cannabis co-use: how young adults start, escalate, and maintain dual use

  This project sees how 18–30-year-olds who use cannabis weekly start, escalate, and keep using either daily cigarettes or daily nicotine vapes.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07439471

• Carcinogen and toxicant exposure among young adults who co-use e-cigarettes and cannabis

  This project will measure nicotine, cannabis, and toxicant levels in blood and urine and compare use behaviors in 18–25-year-olds who primarily use e-cigarettes, cannabis, or both.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07167225

• How menthol and cooling agents change the appeal of oral nicotine pouches

  This test checks whether menthol, a synthetic cooling agent (WS-3), or both make oral nicotine pouches more appealing and better at relieving cravings for adult cigarette smokers.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07111234

• Testing how well smokers can identify cigarette flavors

  This study tests how well daily smokers can recognize different flavors in menthol cigarettes to understand how it affects their smoking habits.

  Recruiting Early Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06816459

• Oral nicotine pouches versus patches and lozenges to reduce cigarette use in rural Appalachia

  This compares oral nicotine pouches with nicotine patches and lozenges to see if they help adults in rural Appalachia who smoke cut down or quit cigarettes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06763536

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.